Repligen’s Strong Market Position and Growth Potential Justify Buy Rating Amid Minimal Tariff Exposure

Leerink Partners analyst Puneet Souda maintained a Buy rating on Repligen (RGEN – Research Report) on April 29 and set a price target of $200.00.

Puneet Souda has given his Buy rating due to a combination of factors that highlight Repligen’s strong position in the bioprocessing market. The company demonstrated impressive growth potential, with a long-term growth rate projected between 15-20% or more. Repligen’s recent quarterly performance exceeded expectations, showcasing robust order momentum despite challenging market conditions. This positive trend is supported by the company’s strategic initiatives to mitigate tariff impacts, with over 90% of its US sales being manufactured domestically, thus minimizing exposure to tariffs.
Furthermore, Repligen’s management has been proactive in addressing potential cost pressures by implementing surcharges and pricing strategies to offset higher costs. The company’s exposure to tariffs is limited, with only a small percentage of sales affected, and efforts are underway to regionalize production to further reduce risks. The bioprocessing sector’s recovery, coupled with Repligen’s strong order growth and minimal tariff exposure, underpins Souda’s optimistic outlook and the raised price target of $200.

In another report released yesterday, RBC Capital also reiterated a Buy rating on the stock with a $189.00 price target.

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is neutral on the stock.